863 results on '"Dubberke, Erik R."'
Search Results
2. Gut microbiome correlates of recurrent urinary tract infection: a longitudinal, multi-center study
3. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
4. Redefining Clostridioides difficile infection antibiotic response and clinical outcomes
5. The impact on central line-associated bloodstream infection rates following the introduction of a closed system transfer device in oncology wards
6. American Society for Transplantation and Cellular Therapy Series: #5—Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients
7. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial
8. Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting
9. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
10. Comparison of Clostridioides difficile nucleic acid amplification test (NAAT) results using fresh and frozen stool specimens and rectal swabs
11. 691. Association between Clostridioides difficile Colonization, Rectal Swab NAAT Positivity, and Environmental Contamination
12. 678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
13. 2956. Increased Microbiota Alpha Diversity is Associated with Decreased Hospital Mortality in Medical Intensive Care Unit Patients
14. 366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
15. Risk factors for hospital-onset Clostridioides difficile infections before and during the severe acute respiratory syndrome coronavirus 2 pandemic
16. Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
17. Introduction to A Compendium of Strategies to Prevent Healthcare-Associated Infections In Acute-Care Hospitals: 2022 Updates
18. Reply to Million et al
19. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
20. Performance of laboratory tests for detection for Clostridioides difficile: A multicenter prospective study in Japan
21. Clostridioides (Clostridium) difficile infection burden in Japan: A multicenter prospective study
22. Can prediction scores be used to identify patients at risk of Clostridioides difficile infection?
23. Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient
24. Reprint of: Overview and changing epidemiology of Clostridium difficile infection
25. Genomic surveillance ofClostridioides difficiletransmission and virulence in a healthcare setting
26. Executive Summary: A Compendium of Strategies to Prevent Healthcare-Associated Infections in Acute-Care Hospitals: 2022 Updates
27. Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
28. Which trial do we need? A sequential multiple Assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence
29. Effect of Fecal Microbiota, live-jslm (RBL) on Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
30. Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults
31. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
32. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children : 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
33. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection
34. Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
35. Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections
36. Frequent Hospital Readmissions for Clostridium difficile Infection and the Impact on Estimates of Hospital-Associated C. difficile Burden
37. Comparing intervention strategies for reducing Clostridioides difficile transmission in acute healthcare settings: an agent-based modeling study
38. Which trial do we need? A sequential multiple assignment randomized trial to determine the optimal Clostridioides difficile treatment sequence
39. 271 - Clostridial and Clostridioides Infections
40. Early coronavirus disease 2019 (COVID-19) pandemic effects on individual-level risk for healthcare-associated infections in hospitalized patients
41. Evaluation of the NG-Test CARBA 5 Lateral Flow Assay with an IMP-27-Producing Morganella morganii and Other Morganellaceae
42. Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
43. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update
44. Walk before you run: Feasibility challenges and lessons learned from the PROCLAIM study, a multicenter randomized controlled trial of misoprostol for prevention of recurrent Clostridioides difficile during COVID-19
45. Clostridioides difficileinfection across the lifespan: Estimation using life tables
46. Microbiology Clinical Culture Diagnostic Yields and Antimicrobial Resistance Proportions before and during the COVID-19 Pandemic in an Indian Community Hospital and Two US Community Hospitals
47. Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
48. Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection
49. Impact of the Severe acute respiratory syndrome coronavirus 2 pandemic on mortality associated with healthcare-associated infections
50. Safety and Tolerability of Misoprostol in Adults with Clostridioides Difficile Infection – the Proclaim Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.